BRCA2 ‐positive lung adenocarcinoma treated with olaparib: A case report

A 66-year-old woman diagnosed with stage IVA lung adenocarcinoma underwent multiple lines of treatment, including chemotherapy and targeted therapies. After discovering a BRCA2 gene mutation through genomic profiling, she initiated olaparib treatment, resulting in approximately 2  years of stable disease. AbstractA 66-year-old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4  years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First-line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brain metastases. The patient later underwent second-line pemetrexed treatment, followed by t hird-line nivolumab, fourth-line docetaxel and bevacizumab, fifth-line tegafur-gimeracil-oteracil, and sixth-line gemcitabine. Two years ago, after observing an increase in the primary lesion and carcinoembryonic antigen levels (104.0 ng/mL), a computed tomography-guided biopsy was performed from the primary site of lung cancer. A cancer genomic profiling test (FoundationOne® CDx cancer genome profile) revealed a breast cancer susceptibility (BRCA) 2 gene mutation. Therefore, she started taking olaparib. The treatment led to stable disease for approximately 2 years.

Source: Respirology Case Reports - March 7, 2024 Category: Respiratory Medicine Authors: Takumi Motohashi, Kazutoshi Isobe, Takahiro Yoshizawa, Yusuke Usui, Hiroshige Shimizu, Muneyuki Sekiya, Shion Miyoshi, Yasuhiko Nakamura, Naohisa Urabe, Susumu Sakamoto, Sakae Homma, Sota Sadamoto, Naobumi Tochigi, Kazuma Kishi Tags: CASE REPORT Source Type: research